Charm Therapeutics - About the company
Charm Therapeutics is a series B company based in London (United Kingdom), founded in 2021 by David Baker and Laksh Aithani. It operates as a Developer of menin inhibitors designed for acute myeloid leukemia treatment. Charm Therapeutics has raised $150M in funding from investors like New Enterprise Associates, Orbimed and SR One, with a current valuation of £*****. The company has 100 active competitors, including 32 funded and 22 that have exited. Its top competitors include companies like Ossium Health, Rigel and Ajax.
Company Details
Developer of menin inhibitors designed for acute myeloid leukemia treatment. The focus is on designing structurally optimised inhibitors that bind within the KMT2A interface. The aim is to overcome treatment resistance in acute myeloid leukemia.
- Website
- charmtx.com
- Social
- Email ID
- *****@charmtx.com
Key Metrics
Founded Year
2021
Location
London, United Kingdom
Stage
Series B
Total Funding
$150M in 3 rounds
Latest Funding Round
Post Money Valuation
£***** as on Oct 26, 2022
Investors
Ranked
10th among 100 active competitors
Annual Revenue
£1M - £10M as on Dec 31, 2025
Employee Count
29 as on Sep 30, 2026
Similar Companies
Legal entities associated with Charm Therapeutics
Charm Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Charm Therapeutics Limited CIN: 13641471 , United Kingdom, Active | Sep 23, 2021 | £1M - £10M (As on Dec 31, 2025) | 16 (As on Jan 31, 2022) |
Sign up to download Charm Therapeutics' company profile
Charm Therapeutics's funding and investors
Charm Therapeutics has raised a total funding of $150M over 3 rounds. Its first funding round was on Jun 09, 2022. Its latest funding round was a Series B round on Aug 19, 2025 for $*****. 6 investors participated in its latest round. Charm Therapeutics has 13 institutional investors.
Here is the list of recent funding rounds of Charm Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 19, 2025 | 1610016 | Series B | 9763481 | 4383635 | 9150174 | 2407061 |
Apr 14, 2023 | 8120956 | Series A | 7577334 | 4725197 | 4643341 | |
Jun 09, 2022 | 4905316 | Series A | 5745246 | 2384720 |
Access funding benchmarks and valuations. Sign up today!View details of Charm Therapeutics's funding rounds and investors
Charm Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Charm Therapeutics are David Baker and Laksh Aithani. Laksh Aithani is the CEO of Charm Therapeutics.
Here are the details of Charm Therapeutics' key team members:
- David Baker: Co-Founder of Charm Therapeutics.
- Laksh Aithani: Co-Founder & CEO of Charm Therapeutics.
View details of Charm Therapeutics's Founder profiles and Board Members
Charm Therapeutics' employee count trend
Charm Therapeutics has 29 employees as of Sep 26. Here is Charm Therapeutics's employee count trend over the years:
Uncover Charm Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Charm Therapeutics's Competitors and alternates
Top competitors of Charm Therapeutics include Ossium Health, Rigel and Ajax. Here is the list of Top 10 competitors of Charm Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Ossium Health 2016, San Francisco (United States), Series C | Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning | $125M | 65/100 | |
2nd | Rigel 1996, San Francisco (United States), Public | Developer of drugs for hematologic disorders, cancer, and rare immune disease | - | 64/100 | |
3rd | Ajax 2019, Cambridge (United States), Acquired | Developer of targeted therapies for the treatment of hematologic malignancies | $135M | 64/100 | |
4th | Sierra Oncology 2003, Vancouver (Canada), Acquired | Developer of targeted therapies to treat cancer | $75M | 63/100 | |
5th | Orca Bio 2016, Menlo Park (United States), Series F | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | $300M | 63/100 | |
6th | MaaT Pharma 2014, Lyon (France), Public | Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42.3M | 61/100 | |
7th |  Adicet Bio 2014, Menlo Park (United States), Public | Developer of immune cell therapeutic solutions for the treatment of cancer | $51M | 61/100 | |
8th | StemlineTherapeutics 2003, New York City (United States), Acquired | Oncology therapeutics innovator focused on transforming cancer patient lives | $15.1M | 58/100 | |
9th | _1559116612173.png?devicePixelRatio=2&height=30&width=30){kind=logo} CERo Therapeutics 2016, San Francisco (United States), Public | Developer of platforms for cellular immunotherapy | $54.8M | 58/100 | |
10th |  Charm Therapeutics 2021, London (United Kingdom), Series B | Developer of menin inhibitors designed for acute myeloid leukemia treatment | $150M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Charm Therapeutics's competitors? Click here to see the top ones
Charm Therapeutics's Investments and acquisitions
Charm Therapeutics has made no investments or acquisitions yet.
Reports related to Charm Therapeutics
Here is the latest report on Charm Therapeutics's sector:
News related to Charm Therapeutics
Filter this listMedia has covered Charm Therapeutics for a total of 3 events in the last 1 year, 3 of them have been about company updates.
•
CHARM Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of CHM-029 for Acute Myeloid LeukemiaGlobeNewswire•Oct 07, 2026•Charm Therapeutics
•
CHARM Therapeutics Announces Formation of Clinical Advisory BoardGlobeNewswire•Aug 18, 2026•Charm Therapeutics
•
CHARM Therapeutics Advances CHM-029 Menin Inhibitor for AMLGlobeNewswire•Nov 13, 2025•Charm Therapeutics
•
CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical OfficerGlobeNewswire•Sep 08, 2025•Charm Therapeutics, BlueSphere Bio
•
Nvidia-backed Charm Therapeutics secures $80M for AI cancer drug clinical trials.Endpoints•Sep 02, 2025•Charm Therapeutics, Nea, Nvidia, SR One and 4 others
•
•
CHARM Therapeutics appoints Dr Beverley Carr as Chief Business OfficerGlobeNewswire•Sep 10, 2024•Charm Therapeutics
•
CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical DevelopmentBioSpace•Apr 30, 2024•Charm Therapeutics
•
CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)GlobeNewswire•Mar 19, 2024•Charm Therapeutics
•
CHARM Therapeutics Bolsters Leadership Team with Key Promotion and Strategic AppointmentBusiness Wire•Dec 12, 2023•Charm Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Charm Therapeutics
Explore our recently published companies
- Fab2 - Austin based, 2023 founded, Series D company
- Photosdesplats.com - 2014 founded, Funding Raised company
- CrestaExim - Ludhiana based, 2026 founded, Unfunded company
- Holly McAlister Design - Unfunded company
- COLOURS GLOBAL - Washington based, 2023 founded, Unfunded company
- Gardens of Annapolis - Annapolis based, Unfunded company
